Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2006 | 1 |
2007 | 2 |
2008 | 1 |
2024 | 0 |
Search Results
4 results
Results by year
Filters applied: . Clear all
Page 1
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.
Science. 2007 May 18;316(5827):1039-43. doi: 10.1126/science.1141478. Epub 2007 Apr 26.
Science. 2007.
PMID: 17463250
Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Engelman JA, Jänne PA.
Engelman JA, et al.
Clin Cancer Res. 2008 May 15;14(10):2895-9. doi: 10.1158/1078-0432.CCR-07-2248.
Clin Cancer Res. 2008.
PMID: 18483355
Review.
Item in Clipboard
Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.
Engelman JA, Mukohara T, Zejnullahu K, Lifshits E, Borrás AM, Gale CM, Naumov GN, Yeap BY, Jarrell E, Sun J, Tracy S, Zhao X, Heymach JV, Johnson BE, Cantley LC, Jänne PA.
Engelman JA, et al.
J Clin Invest. 2006 Oct;116(10):2695-706. doi: 10.1172/JCI28656. Epub 2006 Aug 10.
J Clin Invest. 2006.
PMID: 16906227
Free PMC article.
Item in Clipboard
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.
Engelman JA, Zejnullahu K, Gale CM, Lifshits E, Gonzales AJ, Shimamura T, Zhao F, Vincent PW, Naumov GN, Bradner JE, Althaus IW, Gandhi L, Shapiro GI, Nelson JM, Heymach JV, Meyerson M, Wong KK, Jänne PA.
Engelman JA, et al.
Cancer Res. 2007 Dec 15;67(24):11924-32. doi: 10.1158/0008-5472.CAN-07-1885.
Cancer Res. 2007.
PMID: 18089823
Item in Clipboard
Cite
Cite